Literature DB >> 20865640

Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.

Marie-Agnès Dragon-Durey1, Caroline Blanc, Arnaud Garnier, Johannes Hofer, Sidharth Kumar Sethi, Lothar-Bernd Zimmerhackl.   

Abstract

Non-Shiga toxin-associated hemolytic uremic syndrome (atypical HUS) is a rare form of thrombotic microangiopathy that associates hemolytic anemia, thrombocytopenia, and acute renal failure. The disease has been demonstrated to be linked with a complement alternative pathway dysregulation due to genetic defects but also to development of autoantibodies to factor H (FH), the main plasmatic alternative pathway regulatory protein. In this review, we summarize the more recent data of this autoimmune form of HUS at the level of epidemiology and its clinical and biological features. We propose the performance of anti-FH autoantibodies screening at the very onset of the disease in all cases of HUS to first make the proper diagnosis as early as possible, and second to support an appropriate therapy including early plasma exchanges and immunosuppressive treatments. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865640     DOI: 10.1055/s-0030-1262885

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  18 in total

1.  Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies.

Authors:  Tomohiro Udagawa; Yaeko Motoyoshi; Yu Matsumura; Akira Takei; Shohei Ariji; Eisaku Ito; Motoko Chiga; Masayuki Nagasawa; Tomohiro Morio; Shuki Mizutani
Journal:  CEN Case Rep       Date:  2013-09-12

Review 2.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

3.  Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome.

Authors:  Wei-Yi Guo; Di Song; Xiao-Rong Liu; Zhi Chen; Hui-Jie Xiao; Jie Ding; Shu-Zhen Sun; Hong-Yan Liu; Su-Xia Wang; Feng Yu; Ming-Hui Zhao
Journal:  Pediatr Nephrol       Date:  2018-10-12       Impact factor: 3.714

Review 4.  Defective complement inhibitory function predisposes to renal disease.

Authors:  Anuja Java; John Atkinson; Jane Salmon
Journal:  Annu Rev Med       Date:  2012-11-01       Impact factor: 13.739

Review 5.  Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited.

Authors:  Elizabeth C Miller; Nicole M Chase; Peter Densen; Mary K Hintermeyer; James T Casper; John P Atkinson
Journal:  Clin Immunol       Date:  2012-09-28       Impact factor: 3.969

Review 6.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

7.  Renal function in normal and disordered pregnancy.

Authors:  Wael Hussein; Richard A Lafayette
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-01       Impact factor: 2.894

8.  Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil?

Authors:  Lucie Matrat; Justine Bacchetta; Bruno Ranchin; Corentin Tanné; Anne-Laure Sellier-Leclerc
Journal:  Pediatr Nephrol       Date:  2021-03-28       Impact factor: 3.714

9.  Successful treatment of DEAP-HUS with eculizumab.

Authors:  Damien Noone; Aoife Waters; Fred G Pluthero; Denis F Geary; Michael Kirschfink; Peter F Zipfel; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-11-20       Impact factor: 3.714

Review 10.  Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring.

Authors:  Franca Iorember; Anjali Nayak
Journal:  Pediatr Nephrol       Date:  2020-06-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.